SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amidst intense community debate over recent escalations in Iran, with investors and social media users fiercely divided over the administration's foreign policy, the impact on global energy markets, and the company's broader political associations. The community is actively parsing conflicting signals regarding potential peace negotiations and the financial health of the platform, fueling a high-volume discussion that mirrors the polarized nature of the current political environment.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts is currently a major focus for investors navigating sector-wide volatility, with the community actively debating the company's valuation against its long-term growth prospects in both brick-and-mortar and digital gaming. Market participants are closely watching the balance between regional casino performance, international expansion opportunities, and the competitive pressures from emerging prediction market platforms that are shifting traditional betting behaviors.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors react to activist investor Nelson Peltz signaling that the stock is significantly undervalued, sparking intense speculation regarding a potential buyout or privatization. The community is actively debating the stock's future, weighing the merits of the company's dividend yield and turnaround strategy against frustration over the delayed search for a new CEO.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community reacts to the launch of its Super App, with bullish investors highlighting its potential to redefine payroll infrastructure and drive institutional adoption alongside key ecosystem partnerships. While some users are focused on accumulating during volatility, others are debating the project's long-term utility versus market skepticism following recent token unlocks.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors react to a strong quarterly earnings report and upward-revised fiscal guidance, with the company highlighting record data center demand fueled by AI infrastructure expansion. The community is actively discussing the stock's potential for a breakout, driven by analyst upgrades and momentum in custom silicon and optical interconnect technologies.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as the stock continues to attract value-focused investors following a strong earnings beat and raised full-year guidance. The community is actively discussing the company's growth portfolio, specifically the performance of Opdivo and Reblozyl, as investors weigh these gains against ongoing generic competition and patent cliff concerns.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is capturing intense market attention as traders react to significant institutional investments from firms like Point72 and ongoing aggressive open-market buying by the CEO. The community is focused on the potential for a strategic partnership or buyout, viewing the firm's late-stage clinical data as a catalyst for a possible short squeeze given the relatively limited tradable float.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is drawing significant attention as investors react to ongoing lobbying efforts by prominent figures like Bill Ackman, who are pushing for the government to divest its stake in the mortgage finance firms. The community is sharply divided between those viewing the recent price action as a strategic buying opportunity for a long-term 'conservatorship exit' play and those skeptical of the timeline given the political complexity and lack of official milestones.

Woodside Energy Group Ltd. engages in the exploration, evaluation, development, and production of hydrocarbon and oil and gas properties. It operates through the following segments: North West Shelf, Pluto, Australia Oil, Wheatstone, Development, and Others. The North West Shelf segment produces liquefied natural gas, pipeline natural gas, condensate, liquefied petroleum gas and crude oil from the North West Shelf ventures. The Pluto segment develops liquefied natural gas in assigned permit areas. The Australia Oil segment is involved in the exploration, evaluation, development, production and sale of crude oil in assigned permit areas. The Wheatstone segment is involved in the exploration, evaluation, and development of liquefied natural gas, pipeline natural gas, and condensate. The Development segment includes the exploration of gas resources in Scarborough, Sangomar, and other project areas. The Other segment is composed of the activities undertaken by exploration, international and Sunrise Business Units. The company was founded on July 26, 1954 and is headquartered in Perth, Australia.

Woodside Energy Group Ltd - ADR

Woodside Energy is trending as investors monitor ongoing disruptions in the global LNG market, specifically concerns surrounding key transit chokepoints and the ripple effects on international supply chains. Community sentiment is largely focused on the company's strategic positioning to capture higher pricing amid these supply shortages, while some discussions center on the risks and opportunities associated with potential new infrastructure and capacity expansion projects.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is navigating significant volatility as the industry grapples with an unprecedented government shutdown that has triggered FAA-mandated flight capacity cuts and severe air traffic controller staffing shortages. Investors are intensely debating whether the airline's premium loyalty model provides a durable margin cushion or if the escalating operational disruptions and fuel price pressures from broader Middle East instability will weigh on upcoming performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

<ul class="summary-bullets"><li>While the patent was granted in September 2025, it had to pass a 6-month opposition period.</li><li>The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer.</li><li>AIM is seeking an orphan drug designation in Japan for its treatment.</li></ul>Shares of AIM ImmunoTech Inc (AIM) gave up some of its pre-market gains and was up more than 60% on Wednesday, after the company said that a Japanese patent using its proprietary Ampligen in combination with checkpoint inhibitors to treat cancer was fully approved in the country.While the patent was granted in September 2025, it had to pass a 6-month opposition period, AIM said. The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer. The company holds similar patents in the U.S. and the Netherlands.AIM, which already holds orphan drug designations for pancreatic cancer in the U.S. and Europe, also plans to seek a similar designation in Japan.<h2 class="st-heading-2">DURIPANC Study Update</h2>Earlier this month, AIM ImmunoTech partnered with Thermo Fisher Scientific’s PPD clinical research unit to design a planned Phase 3 trial of Ampligen for late-stage pancreatic cancer.&nbsp;The company also highlighted encouraging results from its ongoing DURIPANC study, including improvements in progression-free and overall survival. The trial is being conducted in collaboration with AstraZeneca and Erasmus Medical Center."Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM’s development of Ampligen as a therapy for pancreatic cancer," said CEO Thomas K. Equels."AIM’s scientific team will work closely with Thermo Fisher’s experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to 'extremely bullish' from 'bearish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/AIMS_jpg_04ac5ff737.webp" alt="AIMS.jpg">One user said the RSI has cooled and its time for the next leg of the rally.<stembedurl>https://stocktwits.com/Chessdoc/message/647888049</stembedurl>Year-to-date, the stock has climbed 1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Why Did AIM Stock Jump 60% Today?

The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.

Equity

Are Medical Stocks Lagging  AIM ImmunoTech (AIM) This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year.

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions

HNST, BROS, AIM, MASI, and CTSH are spotlighted as top-ranked stocks with rising P/E ratios and strong earnings momentum.

Bet On 5 Top-Ranked Stocks With Rising P/E 

Tap these five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are The Honest Company, Dutch Bros, AIM ImmunoTech, Masimo and Cognizant Technology Solutions.

All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy

AIM ImmunoTech (AIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

This account has been verified as an official AIM representative.

Verified Account

AIM Immunotech

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

AIM
AIM ImmunoTech

Feed

News

Sentiment

Fundamentals

Info

Latest AIM News

AIMAIM ImmunoTech